GMGuido Mannaioni

Guido Mannaioni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guido Mannaioni has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prenatal Alcohol Exposure Dysregulates the Glutamatergic Synapse Composition in the Prefrontal Cortex of Adolescent Mice

    by Beatrice Rizzi, Francesca Mottarlini, Valentina Scianaro, Fabio Fumagalli, Guido Mannaioni, Lucia Caffino, Elisabetta Gerace

    Introduction/Objective: Prenatal alcohol exposure (PAE) is a leading preventable cause of neurodevelopmental disorders collectively known as fetal alcohol spectrum disorders (FASD). Since glutamatergic signaling is essential for brain development and synaptic plasticity, we investigated whether PAE alters the molecular composition of the glutamatergic synapses in the prefrontal cortex (PFC) in adolescent mice. Methods: To model PAE, pregnant C57Bl/6J mice were given 10% ethanol (EtOH) voluntarily during the first 10 days of gestation (GD 0-10), corresponding to the first trimester of human pregnancy. The postsynaptic expression of AMPA and NMDA receptor subunits and related scaffolding proteins was then analyzed in the PFC of PAE adolescent offspring by Western blotting. Results: PAE significantly altered the molecular composition of glutamatergic postsynaptic densities, reducing GluA1 and increasing GluA2 -containing AMPA receptors, together with increased GluN1/GluN2A NMDA receptor expression, altering synaptic scaffolding proteins, and enhancing αCaMKII phosphorylation. Discussion: These findings indicate that PAE alters the subunit composition, stabilization, and localization of NMDA and AMPA receptors, inducing persistent molecular remodeling of excitatory synapses in the adolescent PFC. The reorganization of the cortical synapses may potentially disrupt synaptic plasticity and cortical network maturation. Conclusions: These persistent alterations may help explain impaired synaptic plasticity and cognitive and behavioral deficits previously observed in FASD, including impairments in recognition memory, exploratory behavior, and reward processing.

  • Open Access

    Interferon‐γ Mitigates Oxaliplatin‐Induced Neurotoxicity: Analogies With Connexin 43

    by Alessandra Toti, Valentina Ferrara, Elena Lucarini, Laura Micheli, Clara Ciampi, Francesco Margiotta, Daniel Venturi, Carmen Parisio, Elisabetta Gerace, Lorenzo Curti, et al.

    Aims: Chemotherapy‐induced neuropathy is a major side effect of platinum‐based drugs such as oxaliplatin. Given the context‐dependent pro‐inflammatory or neuroprotective actions of interferon‐γ (IFN‐γ), this study investigated its role in an in vitro model of oxaliplatin‐induced neurotoxicity (OIPN). Methods: Rat organotypic spinal cord slices were exposed to oxaliplatin to model chemotherapy‐induced neurotoxicity responses in vitro. IFN‐γ cytotoxicity was assessed at 6 and 24 h. Neurotoxicity, inflammatory mediators, neurotrophic factors, and markers of glial and neuronal activation were analyzed by biochemical and immunohistochemical assays. Connexin 43 (Cx43) was assessed using Gap19 and Gap27 to probe hemichannel and gap‐junction contributions. Electrophysiological recordings characterized neuronal excitability. Results: IFN‐γ (6.5–200 ng/mL) was non‐toxic and, at 65 ng/mL, significantly reduced oxaliplatin‐induced neurotoxicity, decreasing LDH release and suppressing pro‐inflammatory mediators (CCL2, SerpinA3N, CGRP, substance P, c‐Fos). IFN‐γ modulated its signaling by reducing IFNγR and increasing IRF1 expression. It prevented oxaliplatin‐induced overexpression of neurotrophic factors and reduced glial and neuronal hyperactivation markers, preserving neuronal integrity. IFN‐γ reduced Cx43 expression and hemichannel activity, and Gap19 reproduced selected protective effects. Electrophysiology showed attenuation of oxaliplatin‐induced neuronal hyperexcitability. Conclusion: IFN‐γ attenuates oxaliplatin‐induced neurotoxic responses in an in vitro spinal cord model. The parallel reduction in Cx43 expression and hemichannel activity supports further investigation of Cx43 signaling as a candidate pharmacological target in OIPN.

  • Open Access

    Serum benzylpenicillin levels during treatment for amatoxin poisoning: pharmacokinetic support for OATP1B3 inhibition

    by Andrea Missanelli, Giada Crescioli, Cecilia Lanzi, Francesco Gambassi, Alessandra Ieri, Anita Ercolini, Arianna Totti, Roberto Baronti, Nicoletta Cini, Francesca Luceri, et al.

    Benzylpenicillin has long been included in treatment protocols for amatoxin poisoning based on experimental evidence suggesting inhibition of hepatocellular amatoxin uptake via OATP1B3. However, no human pharmacokinetic data have confirmed whether therapeutic regimens achieve serum concentrations sufficient to inhibit this transporter in vivo. We retrospectively analyzed serum benzylpenicillin concentrations in 16 patients with confirmed amatoxin poisoning treated at the Florence Poison Control Center between 2020 and 2024. All patients received continuous intravenous benzylpenicillin infusion (500,000 IU/kg/day for 48 h, followed by 250,000 IU/kg/day for 48 h) as part of a standardized multimodal protocol. Serum samples (n = 44) were collected during routine care and analyzed using LC-MS/MS. Concentrations were expressed in micromolar (µM) and compared with the reported OATP1B3 inhibitory concentration (IC50 = 25 µM). During the first 48h, all serum samples exceeded the IC50 threshold, with mean concentrations of 265 ± 87 µM at 24 h and 241 ± 74 µM at 48 h. Across all samples, the median concentration was 176 µM (range 45-430 µM), and 93% exceeded 25 µM. Following dose reduction, mean concentrations declined but remained above the IC50 in 66% of samples. No adverse events attributable to benzylpenicillin were observed, and all patients survived to discharge without liver transplantation. Although benzylpenicillin's clinical efficacy has yielded conflicting results across retrospective series, variability in dosing regimens and timing likely accounts for much of this inconsistency. The present findings demonstrate that continuous infusion maintains pharmacologically relevant exposure throughout the critical window of amatoxin hepatocellular uptake, supporting target engagement in vivo. The reduced-dose regimen sustained inhibitory concentrations in most samples, suggesting dose optimization is feasible without compromising pharmacological activity. Continuous intravenous infusion of benzylpenicillin achieves serum concentrations exceeding the in vitro OATP1B3 inhibitory threshold in patients with amatoxin poisoning, providing human pharmacokinetic support for its proposed antidotal mechanism and its continued inclusion in multimodal treatment protocols.

  • Open Access

    A Pilot Study on the Deposition of Drugs in Dental Tissues as Alternative Matrices for Forensic Toxicology

    by Ilenia Bianchi, Emma Croce, Federica Gelli, Alexandra Dimitrova, Francesco Pradella, Beatrice Defraia, Emanuele Capasso, Fabio Vaiano, Guido Mannaioni, Vilma Pinchi

    Teeth may serve as alternative matrices for post-mortem toxicological analysis. Although the mechanism of drug incorporation into dental tissues remains unclear, it is hypothesized that orally ingested substances can permeate dental enamel and reach dentin and the pulp. This study investigated enamel permeability to commonly ingested drugs, considering molecular characteristics (methadone - MET and dextromethorphan hydrobromide - DXM), pH, sugar content, and tooth conditions (intact enamel, cement-enamel junction-CEJ exposure, enamel wear). Sixteen clinically extracted teeth were divided into three groups and immersed in different substances, including MET with sugar, DXM with and without sugar (pH 4.5, 1 mg/ml), and acidified saliva (pH 5-6), simulating an addicted individual's oral environment. Cyclic immersions (substance-saliva-substance) mimicked chronic drug intake for about six weeks. After treatment, each tooth was separated into enamel, dentin, and pulp, and analyzed using liquid-liquid extraction and LC-MS/MS. Preliminary results showed that both MET and DXM can penetrate both the enamel and dentin, reaching the pulp regardless of tooth integrity or molecule type. Acidity and sugar content significantly increased the diffusion. These findings suggest that other substances orally assumed might be endowed with similar effects on dental tissues, especially when combined with sugar or acid solutions, supporting teeth as viable matrices in post-mortem toxicology. However, pulp concentrations may reflect oral contamination rather than systemic levels.


  • Open Access

    Gut microbiota dysbiosis affects intestinal sensitivity through epithelium-to-neuron signaling: novel insights from a colon organoid-based model to improve visceral pain therapy

    by Francesco Margiotta, Elena Lucarini, Alessandra Toti, Lorenzo Curti, Alessio Masi, Tommaso Mello, Gwenaelle Le Gall, Gianluca Mattei, Alberto Magi, David Vauzour, et al.

    Chronic gastrointestinal pain is a hallmark of most intestinal pathologies, yet effective treatments remain elusive given the complexity of the underlying mechanisms. Aiming to investigate the intestinal epithelium contribution to visceral pain modulation in dysbiosis context, we first demonstrated that intracolonic instillation of microbe-free fecal supernatants from mice with post-inflammatory dysbiosis induced by dextran sodium sulfate (FSDSS) provokes visceral hypersensitivity in recipient mice. Epithelium involvement in the response to FSDSS was analyzed through a novel in vitro approach comprising murine epithelial colon organoids and primary dorsal root ganglia (DRG) neurons. FSDSS treatment induced growth and metabolic impairment in colon organoids, which revealed a dysbiosis-driven epithelial dysfunction. Notably, the combination of FSDSS and conditioned medium from FSDSS-treated colon organoids induced an increase in DRG neuron intrinsic excitability, along with greater immunoreactivity to c-Fos and calcitonin-gene related peptide, implicating an integrated role of both microbial and epithelial products in visceral sensitivity regulation. By investigating the underlying signaling, metabolomic analysis revealed reduced levels of short chain fatty acids in FSDSS, such as butyrate, acetate, valerate, and propionate. Moreover, transcriptomic analysis of FSDSS-treated colon organoids showed the dysregulated expression of several signaling factors by which intestinal epithelium may modulate sensory neuron excitability, including proteases, cytokines, neuromodulators, growth factors, and hormones. These findings provide novel insights into the role of gut epithelium in the modulation of sensory neuron excitability under dysbiosis conditions, emphasizing that targeting epithelial-neuronal signaling might represent a promising therapeutic strategy for visceral pain management.


  • Open Access

    Safety of direct oral anticoagulants reversal agents in older patients: an analysis of individual case safety reports of adverse drug reaction from VigiBase®

    by Giada Crescioli, Niccolò Lombardi, Elena Arzenton, Nicoletta Luxi, Stefano Fumagalli, Roberto Bonaiuti, Costanza Cacini, Guido Mannaioni, Gianluca Trifirò, Ugo Moretti, et al.

    Background: Real-world data on adverse drug reactions (ADRs) associated with idarucizumab and andexanet alfa are limited. Aim: This study aimed to assess the frequency, the characteristics and clinical and demographic factors associated with ADRs related to their use. Methods: This is a retrospective analysis of ADR reports collected in Vigibase® until May 31, 2023. Multivariable logistic regression estimated reporting odds ratios (RORs) for serious ADRs, death, and thromboembolic events according to demographical and clinical covariates. Results: A total of 1095 Individual Case Safety Reports (ICSRs) reporting idarucizumab (72%) or andexanet alfa (28%) as suspected/interacting agents were collected. Most of the subjects were males (44.5%), with a median age of 78 years, and exposed to only one suspected/interacting medication (73.6%). ADRs were defined as serious in 88.6% of cases, with a total of 614 (56.1%) fatal cases. Compared to patients without concomitant medications, probability of serious ADRs and death were both higher in those receiving ≥ 5 concomitant medications in the idarucizumab subgroup (ROR 4.04 and 1.66, respectively) and in those receiving 1–4 concomitant medications in the andexanet alfa subgroup (ROR 5.66 and 4.80, respectively). Moreover, the probability of thromboembolic events was significantly lower for subjects aged > 75 years (ROR for 75–84 years 0.55; ROR for ≥ 85 years 0.50). Discussion: In real-world, ADRs associated with idarucizumab and andexanet alfa use are generally serious, resulting in death in a high percentage of subjects. Conclusion: Clinicians should pay particular attention when managing individuals needing these drugs, especially if vulnerable and requiring polytherapy.


  • Open Access

    All-Optical Mapping Reveals Distributed Suppression of Cortical Sensory Responses After Optogenetic Silencing

    by Ambrosone Manuel, Montagni Elena, Resta Francesco, Ulivi Tommaso, Curti Lorenzo, Polverini Federica, Mazzamuto Giacomo, Mannaioni Guido, Masi Alessio, Pavone Francesco Saverio, et al.

    Significance Many fundamental processes of brain computation, such as sensory perception and motor control, heavily rely on the mesoscopic dynamics of activity across the cerebral cortex. Manipulating mesoscale activity and observing its effects across multiple brain regions is crucial for understanding the causal link between cortical dynamics and behavior. Objective The goal of this study was to develop a novel all-optical system that allows inhibition of excitatory neurons while simultaneously monitoring cortical responses at arbitrary sites across the entire dorsal cortex of mice. Methods We combined wide-field imaging and optogenetics to create a mesoscale all-optical approach, enabling simultaneous monitoring and manipulation of cortical activity using light. Intravenous injection of two PHP.eB AAVs enabled the whole-brain co-expression of the red-shifted calcium indicator jRCaMP1b and the inhibitory actuator stGtACR2, with stable expression over several weeks. This system was calibrated, and the effects of inhibition on sensory responses were tested. Results Increasing laser power progressively reduced spontaneous activity at the site of irradiation. A single 5-second pulse on the barrel field cortex significantly decreased the amplitude of sensory-evoked responses, not only in the stimulated region but across the entire stimulated hemisphere. Conclusions This novel all-optical system enables targeted inhibition while concurrently monitoring mesoscale cortical activity. It provides insights into the dynamics of cortical circuits and offers a milestone for investigating the causal links between neuronal activity and behavior. Future research can use this tool to address sensory responsiveness impairments in neurological and neuropsychiatric disorders.

  • Open Access

    Consensus Panel Recommendations for the Pharmacological Management of Breastfeeding Women with Postpartum Depression

    by Georgios Eleftheriou, Riccardo Zandonella Callegher, Raffaella Butera, Marco De Santis, Anna Franca Cavaliere, Sarah Vecchio, Cecilia Lanzi, Riccardo Davanzo, Giovanna Mangili, Emi Bondi, et al.

    Introduction: Our consensus statement aims to clarify the use of antidepressants and anxiolytics during breastfeeding amidst clinical uncertainty. Despite recent studies, potential harm to breastfed newborns from these medications remains a concern, leading to abrupt discontinuation of necessary treatments or exclusive formula feeding, depriving newborns of benefits from mother’s milk. Methods: A panel of 16 experts, representing eight scientific societies with a keen interest in postpartum depression, was convened. Utilizing the Nominal Group Technique and following a comprehensive literature review, a consensus statement on the pharmacological treatment of breastfeeding women with depressive disorders was achieved. Results: Four key research areas were delineated: (1) The imperative to address depressive and anxiety disorders during lactation, pinpointing the risks linked to untreated maternal depression during this period. (2) The evaluation of the cumulative risk of unfavorable infant outcomes associated with exposure to antidepressants or anxiolytics. (3) The long-term impact on infants’ cognitive development or behavior due to exposure to these medications during breastfeeding. (4) The assessment of pharmacological interventions for opioid abuse in lactating women diagnosed with depressive disorders. Conclusions: The ensuing recommendations were as follows: Recommendation 1: Depressive and anxiety disorders, as well as their pharmacological treatment, are not contraindications for breastfeeding. Recommendation 2: The Panel advocates for the continuation of medication that has demonstrated efficacy during pregnancy. If initiating an antidepressant during breastfeeding is necessary, drugs with a superior safety profile and substantial epidemiological data, such as SSRIs, should be favored and prescribed at the lowest effective dose. Recommendation 3: For the short-term alleviation of anxiety symptoms and sleep disturbances, the Panel determined that benzodiazepines can be administered during breastfeeding. Recommendation 4: The Panel advises against discontinuing opioid abuse treatment during breastfeeding. Recommendation 5: The Panel endorses collaboration among specialists (e.g., psychiatrists, pediatricians, toxicologists), promoting multidisciplinary care whenever feasible. Coordination with the general practitioner is also recommended.


  • Open Access

    Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

    by Guido Mannaioni, Fabio Lugoboni

    This articles aims is to provide useful information and insights for the management of opioid agonist therapy by providing an overview that ranges from the characteristics of opioid use disorder patients to the macroscopic phenomena of social-health significance on a national scale, with a particular focus on the Italian territory.


  • Open Access

    Hospitalisations Related to the Combination of ACE Inhibitors and/or Angiotensin Receptor Blockers with Diuretics and NSAIDs: A Post Hoc Analysis on the Risks Associated with Triple Whammy

    by Irene Mattioli, Alessandra Bettiol, Giada Crescioli, Roberto Bonaiuti, Guido Mannaioni, Alfredo Vannacci, Niccolò Lombardi

    This post hoc analysis aimed to assess and characterise adverse events (AEs) related to the triple whammy (i.e., combination therapy of ACE inhibitors, ACE-I, and/or angiotensin receptor blockers, ARBs, with diuretics and non-steroidal anti-inflammatory drugs, NSAIDs) leading to emergency department (ED) visits and/or hospitalisations in the Italian setting. The MEREAFaPS database was analysed. ED visits related to co-treatment with ACE-I and/or ARBs, diuretics, and NSAIDs were considered. Information on the AE (including classification, seriousness, and outcome), suspected and concomitant drugs, and concomitant conditions was retrieved and analysed. Logistic regression was used to estimate the reporting odds ratios (RORs) of hospitalisation associated with the drugs of interest. Between 1 January 2007, and 31 December 2018, 80 patients visited the ED for AEs related to the triple whammy, and a total of 261 suspected drugs were involved. Patients were mostly Caucasian females, with a median age of 85 years, and only 9 of them had renal manifestations. In this subset, drug–drug interaction contributed to kidney injury. Most patients presented a Charlson comorbidity index of 4–5. Overall, 47 patients were hospitalised (58.75%), but no significant differences in the risk of hospitalisation were found according to demographic, clinical, or therapeutic features.